AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Sera Prognostics to Present at the 38th Annual JP Morgan Healthcare Conference

January 13, 2020 GMT

SALT LAKE CITY--(BUSINESS WIRE)--Jan 13, 2020--

Sera Prognostics, Inc., the leading health diagnostics company dedicated to improving the lives of women and babies through individualized prenatal care, will be presenting at the upcoming JP Morgan 2020 Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, January 15 th, at 3:30 p.m. PT.

Gregory C. Critchfield, M.D., M.S., Chairman and CEO, will discuss Sera’s latest achievements and upcoming clinical data read-outs.

Sera’s management will be available for one-on-one meetings with conference attendees after the presentation.

About Sera Prognostics, Inc.

Sera Prognostics is the leading health diagnostics company dedicated to improve the lives of women and babies through individualized prenatal care. Sera delivers pivotal information to physicians to improve health and to improve the economics of healthcare delivery for pregnant women. Sera is developing innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® test objectively reports to a physician the risk of a woman’s premature delivery, enabling earlier proactive interventions designed to improve the health of her baby. Sera is working with other researchers to demonstrate the impact of additional interventions to improve pregnancy outcomes when used in connection with the PreTRM® test to stratify risk of prematurity. Sera Prognostics is located in Salt Lake City, Utah. For more information, please visit the company’s website at www.seraprognostics.com.

About the PreTRM® Test

The PreTRM® test is the only clinically-validated blood test that provides an early and individual risk prediction for spontaneous preterm birth in asymptomatic, singleton pregnancies. The PreTRM® test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM® test can help physicians identify early in the pregnancy (as early as 19 weeks of gestation) which women are at increased risk for premature delivery, enabling more informed clinical decisions based on each woman’s individual risk. The PreTRM® test is ordered by a medical professional. For more information about the PreTRM® test, please visit www.PreTRM.com and the PreTRM® test YouTube Channel. You can also join the conversation on Facebook and @PreTRM.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200113005299/en/

CONTACT: Andrew Sauter, CFO

Sera Prognostics, Inc.

info@seraprognostics.com

(801) 990-0772

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA UTAH

INDUSTRY KEYWORD: HEALTH CONSUMER WOMEN OTHER HEALTH BABY/MATERNITY GENERAL HEALTH

SOURCE: Sera Prognostics, Inc.

Copyright Business Wire 2020.

PUB: 01/13/2020 05:03 AM/DISC: 01/13/2020 05:03 AM

http://www.businesswire.com/news/home/20200113005299/en